Literature DB >> 10140352

Antibiotic therapeutic interchange program: six years of experience.

L Frighetto1, D Nickoloff, P Jewesson.   

Abstract

To assess the long-term impact of a therapeutic interchange program on the use of target antimicrobial drugs, we conducted a retrospective study of target drug utilization at our institution--a 1,000-bed Canadian tertiary care teaching hospital. Data were assessed to determine target drug utilization, incidence of therapeutic interchanges, and patient-target drug exposures. Results showed that the incidence of therapeutic interchanges per patient-target drug exposure decreased from a mean of 23% to 2%, resulting in a total net savings for the target drugs of approximately $1.07 million (Canadian) over 6 years. Prescriber acceptance and low manpower requirements combine to make this a useful method of altering prescribing patterns and reducing drug and drug delivery costs.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 10140352

Source DB:  PubMed          Journal:  Hosp Formul        ISSN: 0098-6909


  4 in total

Review 1.  The expanding role of pharmacy and therapeutics committees. The 1990s and beyond.

Authors:  W E Wade; W J Spruill; A T Taylor; R L Longe; D W Hawkins
Journal:  Pharmacoeconomics       Date:  1996-08       Impact factor: 4.981

2.  Systematic literature review of the methodology for developing pharmacotherapeutic interchange guidelines and their implementation in hospitals and ambulatory care settings.

Authors:  Maria Adrover-Rigo; Maria-Dolores Fraga-Fuentes; Francesc Puigventos-Latorre; Iciar Martinez-Lopez
Journal:  Eur J Clin Pharmacol       Date:  2018-10-19       Impact factor: 2.953

3.  Implementation and evaluation of a preprinted perioperative antimicrobial prophylaxis order form in a teaching hospital.

Authors:  P Au; S Salama; C Rotstein
Journal:  Can J Infect Dis       Date:  1998-05

4.  Cost-effectiveness analysis of enoxaparin versus unfractionated heparin for acute coronary syndromes. A Canadian hospital perspective.

Authors:  R M Balen; C A Marra; P J Zed; M Cohen; L Frighetto
Journal:  Pharmacoeconomics       Date:  1999-11       Impact factor: 4.981

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.